4.8 Article

Potent antibody immunity to SARS-CoV-2 variants elicited by a third dose of inactivated vaccine

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Editorial Material Immunology

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity

Simon D. Pollett et al.

Summary: This study characterizes 24 vaccine-breakthrough infections in mostly young healthy individuals, finding that while none required hospitalization, some experienced severe symptoms and shed high levels of live virus. The infecting genotypes included variant-of-concern (VOC) and non-VOC strains.

CLINICAL INFECTIOUS DISEASES (2022)

Review Cell Biology

Development and deployment of COVID-19 vaccines for those most vulnerable

Wayne C. Koff et al.

Summary: The development and global deployment of COVID-19 vaccines are crucial in ending the pandemic, but challenges remain in elderly populations and low-resource settings, making distribution and vaccination efforts difficult.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Article Medicine, General & Internal

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Ezgi Hacisuleyman et al.

Summary: Despite evidence of vaccine efficacy, two fully vaccinated individuals developed mild symptoms of Covid-19 and were infected with variants of SARS-CoV-2. Sequencing of the virus isolates revealed novel mutations, highlighting the potential risk of illness post-vaccination and subsequent infection with variant virus. Efforts to prevent, diagnose, and characterize variants in vaccinated individuals are crucial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Review Microbiology

The success of SARS-CoV-2 vaccines and challenges ahead

Kanta Subbarao

Summary: The development of effective SARS-CoV-2 vaccines is facing challenges in preventing asymptomatic and mild infections, potential updates required due to the emergence of variants with mutations, and concerns about the longevity of vaccine-induced immunity. Coordination in global surveillance, updating vaccines, and potential re-vaccination may be necessary to address these challenges.

CELL HOST & MICROBE (2021)

Article Immunology

mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants

Aurelien Sokal et al.

Summary: This study examined the MBC responses in recovered and naive individuals after mRNA vaccination against SARS-CoV-2, finding that the MBC pool in recovered individuals expanded selectively, matured further, and had potent neutralizers against VOCs. Naive individuals displayed weaker neutralizing serum responses, but a significant portion of their RBD-specific MBCs showed high affinity to multiple VOCs, suggesting potential efficient response to VOCs in naive vaccinees.

IMMUNITY (2021)

Article Biochemistry & Molecular Biology

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Talia Kustin et al.

Summary: Breakthrough SARS-CoV-2 infections post-vaccination may be caused by B.1.1.7 or B.1.351 variants, indicating the importance of robust vaccination. Reduced vaccine effectiveness against these variants was observed in the study, highlighting the need for continued surveillance and enhanced vaccination efforts.

NATURE MEDICINE (2021)

Letter Medicine, General & Internal

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Ann R. Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Review Immunology

Viral targets for vaccines against COVID-19

Lianpan Dai et al.

Summary: The urgent need for vaccines to control the COVID-19 pandemic has led to the rapid development of multiple vaccine candidates, with some showing positive results in late-stage clinical trials. This article discusses the viral elements used in these candidates, the reasons why they are good targets for the immune system, and their implications for protective immunity. Dai and Gao highlight the importance of selecting the right viral targets in vaccine development to ensure an effective immune response and the overall safety and efficacy of the vaccine.

NATURE REVIEWS IMMUNOLOGY (2021)